{
  "schema_version": 1,
  "scope": "Hash-bound derived original SBD authorization dates from three corroborating original NOC passages in each final-checkpoint source. Original dhpp-html-v9 bytes, parser version, source hashes, acquisition dates and authorization conditions are preserved.",
  "created_at": "2026-09-10T07:46:49.986233+00:00",
  "reviewed_by_ai": true,
  "interim_report_sha256": "83b05691996ab449b8076d3c8e7ec6293a630936bed4b9c7ad5173a1561279c3",
  "records": [
    {
      "resource_id": "SBD1715956069651",
      "brand": "Comirnaty Original/Omicron BA.1",
      "raw_sha256": "78a14a26cfb9f88ef2406182013691c6a7f5bfdf839f774f82e032e5d0439e9c",
      "normalized_sha256": "bdddbb8b3610d364f668070e708e9cbfa29982928192b282437d01609a2b9706",
      "original_authorization_date": "2022-10-21",
      "date_basis": "derived_from_corroborated_original_noc_passages",
      "official_url": "https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1715956069651",
      "original_nds_control_number": "266189",
      "base_decision_date_required": "",
      "base_parser_version_required": "dhpp-html-v9",
      "reviewed_by_ai": true,
      "passages": [
        {
          "source_field_index": 29,
          "tag": "tr",
          "text": "NDS # 266189 2022-07-25 Issued NOC (subject to terms and conditions) 2022-10-21 NOC issued for New Drug Submission. Terms and conditions were imposed on the authorization.",
          "sha256": "013af0687485e5612711b474ddc5d60d75c144fee0074144418ff46726caddf4",
          "passage_label": "Original NDS PAAT row"
        },
        {
          "source_field_index": 37,
          "tag": "p",
          "text": "On October 21, 2022, Health Canada issued a Notice of Compliance (NOC), subject to terms and conditions, to BioNTech Manufacturing GmbH for Comirnaty Original/Omicron BA.1.",
          "sha256": "01ebd0ac1035e5e43ef9af28a228492fd426b8cfa90d986a3e4a1f0255cbb775",
          "passage_label": "Original authorization statement in SBD body"
        },
        {
          "source_field_index": 183,
          "tag": "tr",
          "text": "Notice of Compliance issued by Director General, Biologic and Radiopharmaceutical Drugs Directorate 2022-10-21",
          "sha256": "0be47a66d65d106e6402b810dc77faebf562f24ba02a6d444b38a83d3ac2a61b",
          "passage_label": "Original NOC issuance milestone"
        }
      ],
      "control_number_field": {
        "locator": "source_fields[36].text",
        "text": "New Drug Submission Control Number: 266189"
      },
      "source_acquired_at": "2026-09-10T06:43:29.211Z"
    },
    {
      "resource_id": "SBD1745405201062",
      "brand": "Tavneos",
      "raw_sha256": "8a68644af14cf3a612a05c1fc238b9dde22344582831e9930515c9a89520a721",
      "normalized_sha256": "64c4a40ad36616f2d8c396605eaf815293c3f98186bfa71e6237c67cba14f230",
      "original_authorization_date": "2022-04-14",
      "date_basis": "derived_from_corroborated_original_noc_passages",
      "official_url": "https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1745405201062",
      "original_nds_control_number": "248255",
      "base_decision_date_required": "",
      "base_parser_version_required": "dhpp-html-v9",
      "reviewed_by_ai": true,
      "passages": [
        {
          "source_field_index": 39,
          "tag": "tr",
          "text": "NDS # 248255 2021-04-12 Issued NOC 2022-04-14 NOC issued for the New Drug Submission. A Summary Basis of Decision and a Regulatory Decision Summary were published.",
          "sha256": "7c7211d7d219c695acb7b174fcea71ec41594761c283aef7cc1260c500722030",
          "passage_label": "Original NDS PAAT row"
        },
        {
          "source_field_index": 47,
          "tag": "p",
          "text": "On April 14, 2022, Health Canada issued a Notice of Compliance to Vifor Fresenius Medical Care Renal Pharma Ltd. for the drug product Tavneos.",
          "sha256": "76c15e7a3b0d6d1e0e2198b1b2d11ee46914efabf1e74bb4be9e1f69fe218686",
          "passage_label": "Original authorization statement in SBD body"
        },
        {
          "source_field_index": 113,
          "tag": "tr",
          "text": "Notice of Compliance issued by Director General, Therapeutic Products Directorate 2022-04-14",
          "sha256": "ec8f37431aa3271a499e50c9a22a5b2653896cf46879fad907fd22694105dbb2",
          "passage_label": "Original NOC issuance milestone"
        }
      ],
      "control_number_field": {
        "locator": "source_fields[46].text",
        "text": "New Drug Submission Control Number: 248255"
      },
      "source_acquired_at": "2026-09-10T06:37:37.981Z"
    },
    {
      "resource_id": "SBD1749640931774",
      "brand": "Retevmo",
      "raw_sha256": "7d8a7318af85ec5df90a42073c9046d9fd8cffe04e277d2170a53e3d85b01931",
      "normalized_sha256": "7e73b857b9616ad2bf1bfc1154fcde5b008bcc9788d3259dc7fef6602192e2ab",
      "original_authorization_date": "2021-06-15",
      "date_basis": "derived_from_corroborated_original_noc_passages",
      "official_url": "https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1749640931774",
      "original_nds_control_number": "243748",
      "base_decision_date_required": "",
      "base_parser_version_required": "dhpp-html-v9",
      "reviewed_by_ai": true,
      "passages": [
        {
          "source_field_index": 59,
          "tag": "tr",
          "text": "NDS # 243748 2020-09-10 Issued NOC under NOC/c Guidance 2021-06-15 NOC issued under the Guidance Document: Notice of Compliance with Conditions (NOC/c) for New Drug Submission.",
          "sha256": "9072b7b7cc43eef2112fc9c8ad5a4f42883c174186129b38396a11c7d894c161",
          "passage_label": "Original NDS PAAT row"
        },
        {
          "source_field_index": 68,
          "tag": "p",
          "text": "On June 15, 2021, Health Canada issued a Notice of Compliance under the Notice of Compliance with Conditions (NOC/c) Guidance to Loxo Oncology, Inc. for the drug product Retevmo. The product was authorized under the NOC/c Guidance on the basis of the promising nature of the clinical evidence, and the need for further follow-up to confirm the clinical benefit. Patients should be advised of the fact that the market authorization was issued with conditions.",
          "sha256": "1e7ff3e39f46124d2d86fcd891d11f9e7156033ff5f73ab530cbec6faa22022b",
          "passage_label": "Original authorization statement in SBD body"
        },
        {
          "source_field_index": 188,
          "tag": "tr",
          "text": "Notice of Compliance (NOC) issued by Director General, Therapeutic Products Directorate, under the Notice of Compliance with Conditions (NOC/c) Guidance 2021-06-15",
          "sha256": "b753672b302f58d2023cbef99d282cada5aa9dcf1d36a82127700861fd2cf9cf",
          "passage_label": "Original NOC issuance milestone"
        }
      ],
      "control_number_field": {
        "locator": "source_fields[67].text",
        "text": "New Drug Submission Control Number: 243748"
      },
      "source_acquired_at": "2026-09-10T06:41:02.430Z"
    }
  ],
  "final_checkpoint_sha256": "0f536a591af59c8ae5ccf2b08d2a1c43804ce23fb94362c6756926789186fe34",
  "final_checkpoint_created_at": "2026-09-10T07:50:18.493Z"
}